Literature DB >> 9010454

Detection of clonality and genetic alterations in endometrial pipelle biopsy and its surgical specimen counterpart.

M Esteller1, A García, J M Martínez-Palones, J Xercavins, J Reventós.   

Abstract

Carcinoma of the endometrium is the most frequently diagnosed gynecologic malignancy in the western world. Because endometrial carcinoma is monoclonal in origin, the small samples obtained in endometrial pipelle biopsies can be used in PCR clonal studies to distinguish cancerous from noncancerous lesions. The method used for clonal analysis was based on RFLP of the X chromosome-linked phosphoglycerokinase gene and random inactivation of one X chromosome by methylation in women. Among 50 endometrial pipelle biopsies, 26 (52%) were found to be heterozygous for the above-mentioned polymorphism. Of the samples taken from these informative (ie, heterozygous) patients, six were monoclonal including five cases of endometrial carcinoma and one of endometrial atypical hyperplasia. In each case, the same pattern of monoclonality was present in the surgical specimen counterpart. All of the remaining samples were polyclonal and, when the anatomical pathology data were contrasted, they correlated with nonmalignant endometrium (five secretory, five proliferative, seven atrophic, and three simple hyperplasias). In addition, genetic alterations study of monoclonal endometrial samples revealed a K-ras point mutation and a c-erbB2/neu gene amplification in two different endometrial carcinomas. Both alterations were also detected in the surgical specimens. In addition, a diagnosed set of 10 samples of simple hyperplasia and 5 of atypical hyperplasia were subjected to clonal assay. Among eight informative cases, the three that showed that showed the monoclonal pattern corresponded with cases of atypical hyperplasia. No other genetic alterations were detected in these samples. In conclusion, our data indicate that the detection of clonality in endometrial biopsy samples obtained by pipelle would be a useful application for the early diagnosis of endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010454

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  7 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  Evidence of the monoclonal composition of human endometrial epithelial glands and mosaic pattern of clonal distribution in luminal epithelium.

Authors:  Masaaki Tanaka; Satoru Kyo; Taro Kanaya; Noriyuki Yatabe; Mitsuhiro Nakamura; Yoshiko Maida; Masaru Okabe; Masaki Inoue
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

3.  K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis.

Authors:  G L Mutter; H Wada; W C Faquin; T Enomoto
Journal:  Mol Pathol       Date:  1999-10

4.  Diagnosis of premalignant endometrial disease.

Authors:  G L Mutter
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

5.  hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis.

Authors:  M Esteller; L Catasus; X Matias-Guiu; G L Mutter; J Prat; S B Baylin; J G Herman
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

Review 6.  Methods of molecular analysis: mutation detection in solid tumours.

Authors:  I M Frayling
Journal:  Mol Pathol       Date:  2002-04

7.  Exosome-like vesicles in uterine aspirates: a comparison of ultracentrifugation-based isolation protocols.

Authors:  Irene Campoy; Lucia Lanau; Tatiana Altadill; Tamara Sequeiros; Silvia Cabrera; Montserrat Cubo-Abert; Assumpción Pérez-Benavente; Angel Garcia; Salvador Borrós; Anna Santamaria; Jordi Ponce; Xavier Matias-Guiu; Jaume Reventós; Antonio Gil-Moreno; Marina Rigau; Eva Colas
Journal:  J Transl Med       Date:  2016-06-18       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.